- Business
- Bluestar Adisseo Company (600299.SS), a leading global provider of animal nutrition solutions, engages in the research, development, production and sale of feed additives including methionine (powder and liquid forms such as Rhodimet AT and Rhodimet Nutrition), vitamins (notably vitamin A and vitamin E), enzymes, probiotics, organic selenium, amino acids (lysine, threonine, tryptophan), mycotoxin management products (Unike Plus, Toxy-Nil), antioxidants (Oxy-Nil), specialties for aquaculture (Aqualyso, Lipogest, Sanacore GM, Bacti-Nil Aqua, Apex Branchia), ruminants (Smartamine, Selisseo), swine and poultry; it also offers services such as PNE, Nestor, Asict, DIM, E.Lab and MycoMan. Founded in 1939 in France and headquartered in Beijing, China, the company operates through strategic business units in methionine, vitamins and specialties, serving over 4,200 customers in more than 110 countries across Europe, Asia, North America, the United States and Thailand with 17 production sites and 6 research centers. As a main subsidiary of China National Bluestar (Group) Co., Ltd., Bluestar Adisseo focuses on livestock, aquaculture, swine, ruminants, poultry and pet food sectors with tailored nutritional solutions emphasizing sustainability, animal health and performance. Recent developments include strong Q1 2025 revenue growth of 23% to CNY4.3 billion driven by methionine (+29%) and specialties (+7%), alongside a 67.9% increase in net profit to CNY465 million; H1 2025 net profit rose 22% to CNY740 million with revenue up 17% to CNY8.51 billion, supported by volume growth in liquid methionine (+16%), vitamins and specialties (ruminants +29% via Smartamine, Norfeed +18%). Key projects advancing comprise the 150KT powder methionine plant in Quanzhou (construction on track with sulfuric acid project started), European liquid methionine capacity expansion (full operations by end-2025), 37KT Nanjing specialties blending facility (licensed early 2025 with first sales in March), 30KT European specialties optimization (fully operational), Nanjing wastewater treatment (June 2025 commissioning), new acidifiers for China, FeedKind commercialization in aqua and pet markets, and a private placement refinancing of up to CNY3 billion accepted by the Shanghai Stock Exchange in April 2025 with dividends totaling over 40% payout ratio distributed in March and May.